Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01623284 · ClinicalTrials.gov registry record · Phase 1
PiB PET Scanning in Speech and Language Based Dementias
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
NCT01623284: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01623284 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 168 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01623284, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
Study Summary
The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.
Interventions
- DRUG C-11 PiB
- DRUG F-18 FDG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01623284
The ClinicalTrials.gov registry entry for NCT01623284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which C-11 PiB is the first listed.
NCT01623284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01623284 about?
NCT01623284 is a clinical study titled "PiB PET Scanning in Speech and Language Based Dementias". The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid...
What is the current status of trial NCT01623284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2010-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01623284?
The interventions under investigation include: C-11 PiB (DRUG), F-18 FDG (DRUG).
Who is sponsoring clinical trial NCT01623284?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.